TAG:
cap
Dynacare Sets Sights On Raising $89 Million
By Robert Michel | From the Volume VII No. 15 – October 23, 2000 Issue
CEO SUMMARY: Throughout the 1990s, Dynacare weathered the wholesale restructuring of health services in several key Canadian provinces where it operates. In the United States, it sought to build a national base of lab testing even as lab consolidation raged and capitated managed care cont…
Specialty Labs Prepares For Public Stock Offering
By Robert Michel | From the Volume VII No. 14 – October 2, 2000 Issue
CEO SUMMARY: Stock prices for public lab companies zoomed upwards through 2000. For this reason, executives at Specialty Laboratories, Inc. believe it is an auspicious time for their laboratory to bring an initial public offering (IPO) to market. Company officials recently filed a stock r…
Successful Specialty IPO Can Open Door for Others
By Robert Michel | From the Volume VII No. 14 – October 2, 2000 Issue
CEO SUMMARY: It’s no secret that a handful of laboratory companies would like to complete an initial public offering (IPO). If Specialty Labs’ public offering goes well, expect these lab companies to bring their own stock offerings to the public equity markets. As the number of public…
Bill Bonello Sees Opportunities In Diagnostic Services Companies
By Robert Michel | From the Volume VII No. 14 – October 2, 2000 Issue
CEO SUMMARY: With the clinical laboratory industry now enjoying growing interest by professional investors, THE DARK REPORT traveled to New York City to meet with financial analyst William B. Bonello, of U S Bancorp Piper Jaffray. Bonello co-authored a just-released overview of what he ca…
Is it Early-90s “Deja Vu” For Today’s Lab Industry?
By Robert Michel | From the Volume VII No. 14 – October 2, 2000 Issue
CEO SUMMARY: Stock prices for laboratory and pathology companies have skyrocketed since the new decade of the 2000s dawned on January 1. Is investor optimism warranted by the opportunities ahead in diagnostic testing? Or will history repeat itself if the continuing evolution of American h…
Profitable Prices for New Lab Information Services
By R. Lewis Dark | From the Volume VII No. 13 – September 11, 2000 Issue
ONE RESPONSE TO THE CONTINUED CUTBACKS for laboratory test reimbursement during the 1990s was a deluge of papers and speeches by pathologists and lab executives hammering at the theme that laboratory information possesses the potential to improve the quality of healthcare outcomes while reducing the…
MCOs Asking For More Lab Test Information
By Robert Michel | From the Volume VII No. 13 – September 11, 2000 Issue
CEO SUMMARY: During the past 12 months, managed care companies in Michigan have increased the quantity and quality of the laboratory test information they want from their laboratory providers. Once again, the marketplace is raising the bar for competitive laboratory services. In response,…
Medicare HMO Program Debates Funding Levels
By Robert Michel | From the Volume VII No. 13 – September 11, 2000 Issue
CEO SUMMARY: Medicare+Choice was to offer seniors insurance options that went beyond standard Medicare fee-for-service services.Through the 1990s, seniors enrolled in Medicare HMOs at phenomenal rates. A recent GAO report repeated claims that Medicare HMOs are over-funded, to the tune of …
Quest Diagnostics Emphasizes Venture Capital Investments
By Robert Michel | From the Volume VII No. 13 – September 11, 2000 Issue
ONE SIGNIFICANT business strategy in play at Quest Diagnostics Incorporated is venture capital investing. With $3 billion in sales, Quest Diagnostics is the largest clinical laboratory company in the United States. It understands that the traditional lab sales strategy of marketing …
Accurate Costing of New Pap Technology Proves Interesting
By Robert Michel | From the Volume VII No. 13 – September 11, 2000 Issue
CEO SUMMARY: Various new technologies intended to supplant conventional Pap smear screening must deliver improved clinical performance in a cost-effective manner. Joseph Plandowski, our guest writer,concludes his three-part series on new Pap smear technologies by evaluating actual lab cos…
CURRENT ISSUE

Volume XXXII, No. 10 – July 14, 2025
This issue is strong on different flavors of enforcement that clinical laboratories, whether they want to or not, will need to contend with. Lab stakeholders provide insights that medical labs need to brace for more action to counter pending test reimbursement rate cuts under PAMA. Also, this issue provides the legal and regulatory landscape for clinical labs’ use of AI and how it evolves with the technology. AI is creating legal uncertainty for clinical labs, especially around data privacy and FDA oversight of AI tools in diagnostics.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized